Claims for Patent: 8,021,693

Summary for Patent: 8,021,693

Title:	Methods of organ regeneration using Hox11-expressing pluripotent cells
Abstract:	The invention features methods for increasing or maintaining the number of functional cells of a predetermined type in a mammal (e.g., a human patient), for example, the insulin producing cells of the pancreas, liver cells, spleen cells, or bone cells, that has injured or damaged cells of the predetermined type or is deficient in cells of the predetermined type.
Inventor(s):	Faustman; Denise L. (Boston, MA)
Assignee:	The General Hospital Corporation (Boston, MA)
Application Number:	12/549,714
Patent Claims:	1. A method for increasing or maintaining the number of functional cells of a predetermined type in an organ or tissue of a mammal, wherein said organ or tissue is injured, damaged, or deficient in said functional cells and wherein said organ or tissue is, or is part of, pancreas, spleen, liver, kidney, bone, blood, vascular tissue, brain, spinal cord, nervous system tissue, heart, bile duct, skin, bladder, eye, stomach, intestines, muscle, ligament, cartilage, esophagus, gallbladder, lung, ovaries, prostate, testes, thymus, ureter, urethra, uterus, or fat, said method comprising administering to said mammal a composition enriched in pluripotent cells from an adult mammal, wherein said pluripotent cells endogenously express the Hox ll gene. 2. The method of claim 1, further comprising stimulating said organ or tissue before administering said composition. 3. The method of claim 2, wherein said organ or tissue is stimulated by administering TNF-alpha. 4. The method of claim 2, wherein said organ or tissue is stimulated by administering a TNF-alpha agonist or a TNF-alpha inducing substance. 5. The method of claim 4, wherein said TNF-alpha agonist or TNF-alpha inducing substance is Complete Freund's Adjuvant (CFA), ISS-ODN, microbial cell wall components with LPS-like activity, cholera particles, E. coli heat labile enterotoxin, E. coli heat labile enterotoxin complexed with lecithin vesicles, ISCOMS-immune stimulating complexes, polyethylene glycol, poly(N-2-(hydroxypropyl)methacrylamide), synthetic oligonucleotides containing CpG or CpA motifs, monophosphoryl lipid A, Bacillus Calmette-Guerin, .gamma.-interferon, Tissue Plasminogen Activator, LPS, Interleukin-1, Interleukin-2, UV light, a lymphotoxin, cachectin, a TNFR-2 agonist, an intracellular mediator of the TNFalpha signaling pathway, a NF.kappa.B inducing substance, IRF-1, STAT1, a lymphokine, or the combination of TNF-alpha and an anti-TNFR-1 antibody. 6. The method of claim 1, wherein said composition is enriched in cells which do not express CD45 protein. 7. The method of claim 6, wherein said pluripotent cells are enriched from the peripheral blood or tissue of a mammal by a method comprising: a) providing from the mammal peripheral blood or tissue that contains pluripotent cells; b) separating pluripotent cells from said peripheral blood or tissue; c) separating said pluripotent cells into a first cell population which expresses CD45 antigen on the surface of said cells and a second cell population which predominantly does not express CD45 antigen on the surface of said cells; and d) selecting said second cell population. 8. The method of claim 1, wherein said pluripotent cells are derived from the spleen. 9. The method of claim 1, wherein said pluripotent cells are semi-allogeneic. 10. The method of claim 1, wherein said pluripotent cells are isogeneic. 11. The method of claim 1, wherein said composition comprises cells that present MHC class I and peptide, wherein said MHC class I has at least one allele that matches an MHC class I allele expressed by said mammal. 12. The method of claim 1, further comprising administering to said mammal an agent that selectively inhibits, removes, or kills cell populations that interfere or prevent the trafficking of, differentiation of, or growth of Hox-ll-expressing pluripotent cells. 13. The method of claim 12, wherein said cell populations comprise lymphocytes. 14. The method of claim 12, wherein said agent comprises TNF-alpha. 15. The method of claim 12, wherein said agent comprises a TNF-alpha agonist or a TNF-alpha inducing substance. 16. The method of claim 15, wherein said TNF-alpha agonist or TNF-alpha inducing substance is Complete Freund's Adjuvant (CFA), ISS-ODN, microbial cell wall components with LPS-like activity, cholera particles, E. coli heat labile enterotoxin, E. coli heat labile enterotoxin complexed with lecithin vesicles, ISCOMS-immune stimulating complexes, polyethylene glycol, poly(N-2(hydroxypropyl)methacrylamide), synthetic oligonucleotides containing CpG or CpA motifs, monophosphoryllipid A, Bacillus Calmette-Guerin, .gamma.-interferon, Tissue Plasminogen Activator, LPS, Interleukin-1, Interleukin-2, UV light, a lymphotoxin, cachectin, a TNFR-2 agonist, an intracellular mediator of the TNF-alpha signaling pathway, a NF.kappa.B inducing substance, IRF-I, STATI, a lymphokine, or the combination of TNF-alpha and an anti-TNFR-1 antibody. 17. The method of claim 1, wherein said mammal has an autoimmune disease. 18. The method of claim 17, wherein said disease is alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, autoimmune Addison's disease, autoimmune hemolytic anemia, autoimmune hepatitis, Behcet's disease, bullous pemphigoid, cardiomyopathy, celiac sprue-dermatitis, chronic fatigue immune dysfunction syndrome (CFIDS), chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, cicatricial pemphigoid, CREST syndrome, cold agglutinin disease, Crohn's disease, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia-fibromyositis, Graves' disease, Guillain-Barre, Hashimoto's thyroiditis, hypothyroidism, idiopathic pulmonary fibrosis, idiopathic thrombocytopenia purpura (ITP), IgA nephropathy, insulin dependent diabetes, juvenile arthritis, lichen planus, lupus, Meniere's disease, mixed connective tissue disease, multiple sclerosis, myasthenia gravis, pemphigus vulgaris, pernicious anemia, polyarteritis nodosa, polychondritis, polyglandular syndromes, polymyalgia rheumatica, polymyositis and dermatomyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, Raynaud's phenomenon, Reiter's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, stiff-man syndrome, Takayasu arteritis, temporal arteritis/giant cell arteritis, ulcerative colitis, uveitis, vasculitis, vitiligo, or Wegener's granulomatosis. 19. The method of claim 1, wherein said pluripotent cells are splenocytes. 20. The method of claim 1, wherein said pluripotent cells are obtained from peripheral blood. 21. The method of claim 1, wherein said pluripotent cells can differentiate into two or more different cell types. 22. The method of claim 1, wherein said pluripotent cells are human cells. 23. The method of claim 1, wherein said pluripotent cells express one or more cell markers selected from CD90, CD44, and CD29, but do not express CD34. 24. The method of claim 1, wherein said method comprises administering said pluripotent cells more than once. 25. The method of claim 1, wherein said method comprises administering said pluripotent cells intravenously or intraperitoneally.

Details for Patent 8,021,693

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Teknika Llc	TICE BCG	bcg live	For Injection	102821	06/21/1989		2022-06-27